Date: 2018-09-10
Type of information: Restructuring
Compound:
Company: Thrombogenics (Belgium) now Oxurion (Belgium)
Therapeutic area: Ophtalmological diseases
Type agreement:
Action mechanism:
Disease:
Details:
- • On September 3, 2018, ThromboGenics, a biopharma company focused on developing innovative treatments for back of the eye disorders, and with an innovative pipeline in diabetic eye disease, announced that all name change resolutions proposed at an Extraordinary General Meeting held Monday September 3, 2018, gained shareholder approval. As a result, ThromboGenics will become Oxurion. The name change will be implemented in the next days and weeks. The Company stock ticker symbol will also change from "THR" to "OXUR".
- The new corporate website will be www.oxurion.com .
- Patrik De Haes, MD, CEO of ThromboGenics, comments: "The new name, Oxurion, is designed to better reflect our ambition to deliver best in class therapies for back of the eye disorders. The renaming comes at a moment when we have delivered important clinical milestones and are accelerating the development of our unique pipeline of disease modifying compounds for diabetic eye disease. Moreover, we are also expanding our drug development efforts into new back of the eye indications where there is clear need for improved therapeutic options."
- • On June 27, 2018, ThromboGenics announced its intention to change its name to Oxurion .Subject to the approval of the shareholders' assembly, the name change will become effective in the week commencing September 10, 2018. The name Oxurion is derived from a combination of 'Oxygen' and 'Orion'. Increasing oxygen levels plays a key role in helping prevent and reverse several of the key underlying factors leading to diabetic eye disease. Reference to this concept is in line with the Company's mission to target the onset of these diseases with disease-modifying therapies, as early as possible, to the ultimate benefit of the patients. Orion was a Greek mythological figure who, after being blinded, had his vision restored by Helios, the God of the Sun. This reference captures the Company's mission, which is focused on enhancing vision and fighting blindness by researching and developing innovative pharmacological treatment options for unmet clinical needs in back-of-the-eye diseases.
Financial terms:
Latest news:
- • On September 10, 2018, Oxurion, formerly known as ThromboGenics, announced the start of today's trading under "OXUR" on NYSE Euronext Brussels. Effective today, the launch of a new ticker and website (www.oxurion.com) coincides with the company's name change and highlights its comprehensive approach and renewed focus on the development of best-in-class therapies for back of the eye disorders.
Is general: Yes
